Recent Updates
Recently added Catalysts

Spinal cord stimulation system

Phase 2

Systolic Heart Failure | Unknown | Cardiovascular |Abbott Laboratories|Last Updated: Feb 4, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment20
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01362725Spinal Cord Stimulation For Heart FailurePHASE2 COMPLETED 20Apr 1, 2011Jan 1, 2016Feb 4, 20195 Australia, Hong Kong +1
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Safety and efficacy markers
6 months

Intra and post procedure adverse events, exercise and functional capacity, left ventricular structure and function, inflammatory condition, and quality of life.

Secondary Endpoints
long-term safety
24 months
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Spinal cord stimulationEXPERIMENTAL -
Interventions
NameTypeDescription
Spinal cord stimulation systemDEVICEAn implantable pulse generator (IPG) will deliver low-intensity electrical pulses which travel from the IPG through the leads to the electrodes positioned at the selected nerve fibers to provide the therapeutic stimulation.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 95 Years
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion Criteria: * Patients has a LVEF between 20% and 35% * Patient is in NYHA Class III or in Ambulatory Class IV * Patient has had a SJM implantable cardioverter defibrillator (ICD) device or a SJM CRT-D device implanted \>90 days and is receiving stable medical therapy for HF (\>90 days) at ...

Countries:AustraliaHong KongJapan
Unlock Eligibility Criteria